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Purpose
To investigate whether the Vemurafenib-induced increased
tumor antigen expression, T lymphocyte infiltration and
tumor debulking improve the complete response rate
induced by HD IL-2 in metastatic melanoma and if there is
synergistic toxicity using the drugs in close approximation.
Schema
Adult patients with measurable metastatic or unresectable
Stage III melanoma with no prior therapy and a BRAFV600
mutation who are candidates for HD IL-2 are eligible for
entry into the first cohort of 135 patients (figure 1). Six
weeks of Vemurafenib therapy per package insert precedes
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Figure 1 Treatment of metastatic melanoma with HD IL-2 immunotherapy and targeted agent vemurafenib.
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up to 2 courses of HD IL-2. Vemurafenib is administered
during the outpatient intervals between cycles of HD IL-2
and following completion. A second cohort of up to 50
similar patients already responding or stable with < 18
weeks of Vemurafenib therapy will also be accrued. The
study was amended to permit prior anti-PD-1 therapy.
The primary endpoint is Complete Response (CR) and
near CR at 6 months of therapy.
Current status
Sixteen sites have enrolled patients. 41 patients have
been enrolled to date, 27 in Cohort 1 and 14 in cohort
2. The Data Safety and Monitoring Board performed an
initial safety analysis after the initial 8 patients which
demonstrated no unexpected safety signal. An analysis
of the effect of the combination on Progression Free
Survival in both cohorts will be performed after the first
20% of patients in Cohort 1 have received at least one
course of HD IL-2. The results of this analysis should
be available at the time of the SITC meeting.
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